Metropolis Healthcare Unveils Investor Presentation Highlighting 3-Year Growth Strategy
Metropolis Healthcare's investor presentation outlines a 3-year strategy for profitable growth. It projects FY26 revenue at ₹1,646 crore and targets 14-15% annual revenue growth. Key initiatives include network expansion to 1,000 centers, increasing specialty revenue to 45%, and growing the TruHealth segment to 25%. The company aims for EBITDA margin improvement to 27-28%.
The announcement provides a comprehensive 3-year strategic plan with detailed financial projections and growth drivers, which is highly material for investors and stakeholders.
The presentation details a clear growth strategy with specific financial targets and key initiatives, indicating a positive outlook for the company's future performance.
Metropolis Healthcare Limited has released an investor presentation detailing its strategic roadmap for the next three years, focusing on strengthening its core business and expanding adjacencies to drive shareholder value. The company aims for mid-teen volume-led revenue growth, projecting a CAGR of 17.6% for FY26, reaching ₹1,646 crore. EBITDA is expected to grow at 18.6% CAGR to ₹401 crore, with Profit After Tax at ₹191 crore, reflecting a 22.2% CAGR. The presentation highlights a strategy centered on technology leadership, scientific differentiation, profitable growth, delivering a strong brand promise, and robust governance.
Key growth drivers include expanding the network to 1,000 own centers by FY29, increasing specialty testing revenue to approximately 45% of the total, and growing the TruHealth segment (wellness, radiology, consults) to 25% of revenue. Technology adoption, including AI and automation, is a critical enabler to lift productivity and reduce costs. The company also plans selective, disciplined inorganic growth through acquisitions.
Metropolis reported Q1 FY27 revenue of ₹450 crore, a 17% year-on-year increase, with an EBITDA margin of 25.2%. The guidance for full-year revenue growth is 14-15%, assuming no price increases. The company anticipates EBITDA margin improvement of 100-150 basis points and aims to achieve a margin of 27-28% within three years. The presentation also detailed the company's board composition, governance framework, and shareholding structure, noting the exit of private equity investors.
A plain-language summary of a public exchange filing by Metropolis Healthcare Limited. Read the original for the full detail.